Nanostructured Lipid Carriers for Prolonged Aceclofenac Release: A Comparative Study of Glyceryl Behenate and Tristearin-Based Formulations

Abstract

Objective: This study aims to compare the prolonged release profiles of Aceclofenac encapsulated in nanostructured lipid carriers (NLCs) prepared using Glyceryl Behenate (Compritol 888 ATO) and Tristearin, evaluating which lipid matrix offers more effective sustained drug release.

Materials and Methods

Materials: Aceclofenac, Glyceryl Behenate, Tristearin, MCTs, Polysorbate 80, Soy Lecithin, PVA, dichloromethane, ethanol.

Methods: NLCs were prepared by melting solid and liquid lipids, dissolving Aceclofenac, and adding surfactants and stabilizers. The mixture was homogenized and ultrasonicated. Particle size, zeta potential, and encapsulation efficiency were measured. In vitro release studies were conducted using dialysis bags in PBS, analyzing Aceclofenac content via UV-Vis spectrophotometry.

Results and Discussion: Glyceryl Behenate-based NLCs had a mean particle size of 150 nm and a zeta potential of -25 mV, while Tristearin-based NLCs were 200 nm with a zeta potential of -22 mV. Encapsulation efficiencies were 85% and 80%, respectively. Glyceryl Behenate-based NLCs demonstrated prolonged Aceclofenac release over 48 hours, whereas Tristearin-based NLCs released the drug within 24 hours. The higher encapsulation efficiency and smaller particle size of Glyceryl Behenate-based NLCs contributed to a more sustained release.

Conclusion: Glyceryl Behenate-based NLCs provide a more effective sustained release of Aceclofenac compared to Tristearin-based NLCs, attributed to better encapsulation efficiency, stability, and release profile, making them a superior choice for controlled release formulations.